Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum IMV Inc IMVIF

IMV Inc. is a Canada-based company. The Company has no business operations.

GREY:IMVIF - Post Discussion

IMV Inc > Just as a side note
View:
Post by qwerty22 on Mar 04, 2021 12:37pm

Just as a side note

Merck has had to withdraw Keytruda as a treatment for lung cancer because its efficacy (in terms of OS) is not so strong. 

https://www.clinicaltrialsarena.com/news/merck-withdraws-keytruda-for-lung-cancer-amid-fda-crackdown/

I'm sure they would like that indication back. Does this make the basket trial data in lung cancer more valuable to Merck if it's looking like an improvement over Keytruda alone?

Comment by alphaseeking001 on Mar 04, 2021 1:12pm
I had seen that as well Qwerty.  I'm sure they would absolutely want that indication back.  Volume seems to have been slowing as we've been dropping here.  Hopefully means a bottom may be sooner than later in the short term.
Comment by LR6852 on Mar 04, 2021 1:26pm
It was only withdrawn for small cell lung cancer
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities